These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24685872)

  • 21. Febuxostat: drug review and update.
    Grewal HK; Martinez JR; Espinoza LR
    Expert Opin Drug Metab Toxicol; 2014 May; 10(5):747-58. PubMed ID: 24684266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypercalcemia worsened by the use of furosemide in a patient suffering from allopurinol-induced granulomatous hepatitis.
    Hernández LM; Salinas RM; Cabrera MS; Acosta GP; Henríquez MS; Quintana PP; Díaz JG
    Rev Esp Enferm Dig; 2010 Feb; 102(2):147-8. PubMed ID: 20361854
    [No Abstract]   [Full Text] [Related]  

  • 23. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allopurinol-induced DRESS syndrome with a histologic pattern consistent with interstitial granulomatous drug reaction.
    Kim MS; Lee JH; Park K; Son SJ
    Am J Dermatopathol; 2014 Feb; 36(2):193-6. PubMed ID: 21814129
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety of urate-lowering therapies: managing the risks to gain the benefits.
    Keenan RT
    Rheum Dis Clin North Am; 2012 Nov; 38(4):663-80. PubMed ID: 23137576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Case presentation--tophaceous gout].
    Von Zingel M
    MMW Fortschr Med; 2012 Apr; 154 Suppl 1():8-9. PubMed ID: 23427363
    [No Abstract]   [Full Text] [Related]  

  • 27. [Febuxostat versus allopurinol for hyperuricemia].
    Ziegler R
    Med Monatsschr Pharm; 2006 Oct; 29(10):384. PubMed ID: 17058902
    [No Abstract]   [Full Text] [Related]  

  • 28. Febuxostat hypersensitivity.
    Abeles AM
    J Rheumatol; 2012 Mar; 39(3):659. PubMed ID: 22383358
    [No Abstract]   [Full Text] [Related]  

  • 29. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Febuxostat versus allopurinol for gout.
    Gelber AC
    N Engl J Med; 2006 Apr; 354(14):1532-3; author reply 1532-3. PubMed ID: 16602151
    [No Abstract]   [Full Text] [Related]  

  • 31. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Whelton A; MacDonald PA; Chefo S; Gunawardhana L
    Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Febuxostat provides new gout treatment option.
    Belavic JM
    Nurse Pract; 2010 Mar; 35(3):9-10. PubMed ID: 20164728
    [No Abstract]   [Full Text] [Related]  

  • 33. Febuxostat: hepatic failure.
    Prescrire Int; 2013 Dec; 22(144):297. PubMed ID: 24600733
    [No Abstract]   [Full Text] [Related]  

  • 34. [Pharmacological sheet. Febuxostat, oral (Adenuric)].
    Duh PD; Warnez PM
    J Pharm Belg; 2012 Mar; (1):39-40. PubMed ID: 22536683
    [No Abstract]   [Full Text] [Related]  

  • 35. Approach to the treatment of hyperuricemia.
    Poon SH; Hall HA; Zimmermann B
    Med Health R I; 2009 Nov; 92(11):359-62. PubMed ID: 19999894
    [No Abstract]   [Full Text] [Related]  

  • 36. Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database.
    Gandhi PK; Gentry WM; Bottorff MB
    Semin Arthritis Rheum; 2013 Jun; 42(6):562-6. PubMed ID: 23352248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
    J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Febuxostat].
    Wittköpper K; Emons J; El-Armouche A
    Dtsch Med Wochenschr; 2011 Jun; 136(23):1270-4. PubMed ID: 21607898
    [No Abstract]   [Full Text] [Related]  

  • 40. Allopurinol hypersensitivity syndrome.
    Carpenter C
    Tenn Med; 1997 Apr; 90(4):151-2. PubMed ID: 9088156
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.